Vitasora Health (VHL) H2 2025 earnings summary

Executive summary

• Achieved a major transformation, rebranding from Respiri Limited to Vitasora Health Limited and expanding from a respiratory-focused company to a diversified, technology-enabled leader in chronic care management in the U.S. market.

• Completed the acquisition of Orb Health, accelerating U.S. market penetration, expanding service offerings, and delivering operational efficiencies through integration and cost optimization.

• Ended FY25 with 20,863 active patient programs and $3 million in revenue, supported by a robust sales pipeline covering 1.2 million lives.

• Aligned with U.S. healthcare reform and value-based care mandates, leveraging policy tailwinds and government support for connected health technologies.

• Secured $11 million in firm commitments post-year-end from institutional and long-term shareholders, funding operations through to cash flow breakeven in H1 CY2026.

Financial highlights

• Revenue for FY25 was $3.7 million, including $3.1 million in operating revenue; H2 contributed a record $2.1 million, driven by Orb Health revenues and organic growth.

• Net loss after tax for the year was $10,105,042, compared to $7,129,247 in FY24.

• Operating cash outflow was $9,167,609, up from $6,641,350 in FY24.

• Realized merger synergies post-Orb Health acquisition, reducing combined monthly losses from US$453K to US$305K, an annualized saving of US$1.78 million.

• Held $2,883,969 in inventories and $394,240 in cash at year end.

Outlook and guidance

• Positioned for significant growth, scale, and profitability in FY26, with a proven business model aligned to regulatory and market trends.

• Revenue growth for the next year is expected to be significant, with a five-year model projecting 45% annual growth on average.

• Operations funded through to cash flow breakeven in H1 CY2026, supported by recent capital raises.